UNLIMITED FREE ACCESS TO THE WORLD'S BEST IDEAS

close
Already an Engineering360 user? Log in.

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

Customize Your Engineering360 Experience

close
Privacy Policy

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

ASTM International - ASTM E2891-20

Standard Guide for Multivariate Data Analysis in Pharmaceutical Development and Manufacturing Applications

active
Buy Now
Organization: ASTM International
Publication Date: 1 July 2020
Status: active
Page Count: 7
ICS Code (Pharmaceutics in general): 11.120.01
ICS Code (IT applications in health care technology): 35.240.80
significance And Use:

4.1Â A significant amount of data is generated during pharmaceutical development and manufacturing activities. The interpretation of such data is becoming increasingly difficult. Individual... View More

scope:

1.1Â This guide covers the applications of multivariate data analysis (MVDA) to support pharmaceutical development and manufacturing activities. MVDA is one of the key enablers for process understanding and decision making in pharmaceutical development, and for the release of intermediate and final products after being validated appropriately using a science and risk-based approach.

1.2Â The scope of this guide is to provide general guidelines on the application of MVDA in the pharmaceutical industry. While MVDA refers to typical empirical data analysis, the scope is limited to providing a high level guidance and not intended to provide application-specific data analysis procedures. This guide provides considerations on the following aspects:

1.2.1Â Use of a risk-based approach (understanding the objective requirements and assessing the fit-for-use status);

1.2.2Â Considerations on the data collection and diagnostics used for MVDA (including data preprocessing and outliers);

1.2.3Â Considerations on the different types of data analysis, model testing, and validation;

1.2.4Â Qualified and competent personnel; and

1.2.5Â Life-cycle management of MVDA model.

1.3Â This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety, health, and environmental practices and determine the applicability of regulatory limitations prior to use.

1.4Â This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

Document History

ASTM E2891-20
July 1, 2020
Standard Guide for Multivariate Data Analysis in Pharmaceutical Development and Manufacturing Applications
4.1Â A significant amount of data is generated during pharmaceutical development and manufacturing activities. The interpretation of such data is becoming increasingly difficult. Individual...
November 1, 2013
Standard Guide for Multivariate Data Analysis in Pharmaceutical Development and Manufacturing Applications
4.1 A significant amount of data is being generated during pharmaceutical development and manufacturing activities. The interpretation of such data is becoming increasingly difficult. Individual...
Advertisement